Bayer/Loxo Oncology’s larotrectinib has been granted a priority review by the US Food and Drug Administration, which will consider its use to treat metastatic solid tumours carrying a certain genetic mutation.
Bayer and Loxo Oncology have agreed to work together on the development and commercialisation of two novel cancer therapies, in a deal potentially worth more than $1.5 billion to the latter firm.